Cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: A practical approach

Elena V. Varlamov, Fabienne Langlois, Greisa Vila, Maria Fleseriu

Research output: Contribution to journalReview articlepeer-review

Abstract

Cushing's syndrome (CS) is associated with increased mortality that is driven by cardiovascular, thromboembolic, and infection complications. Although these events are expected to decrease during disease remission, incidence often transiently increases postoperatively and is not complete ly normalized in the long-term. It is important to diagnose and treat cardiovascular, thromboembolic, and infection complications concomitantly with CS treatment. Management of hyperglycemia/diabetes, hypertension, hypokalemia, hyperlipidemia, and other cardiovascular risk factors is generally undertaken in accordance with clinical car e standards. Medical therapy for CS may be needed even prior to surgery in severe and/or prolonged hypercortisoli sm, and treatment adjustments can be made based on disease pathophysiology and drug-drug interactions. Thromboprophylaxis should be considered for CS patients with severe hypercortisolism and/or postoperatively, based on individual risk factors of thromboembolism and bleeding. Pneumocystis jiroveci pneumonia prophylaxis should be considered for patients with h igh urinary free cortisol at the initiation of hypercortisolism treatment.

Original languageEnglish (US)
Pages (from-to)R207-R224
JournalEuropean journal of endocrinology
Volume184
Issue number5
DOIs
StatePublished - May 2021

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing's syndrome: A practical approach'. Together they form a unique fingerprint.

Cite this